Cisplatin + TIL

The combination of cisplatin with tumor-infiltrating lymphocytes (TIL) represents a therapeutic approach that combines chemotherapy with immunotherapy for cancer treatment. Cisplatin is a well-established platinum-based chemotherapeutic agent. Cisplatin works by forming DNA crosslinks that interfere with cell division, leading to apoptosis (programmed cell death) in cancer cells[1]. It's commonly used in combination therapies for various cancers including sarcomas, soft tissue cancers, and many others[1]. However, drug resistance is a significant challenge with cisplatin treatment, which is why combination approaches are often pursued[1]. TIL therapy is an adoptive cell transfer immunotherapy where T cells are isolated from a patient's tumor, expanded ex vivo, and then reinfused to enhance the immune response against cancer cells. The combination of cisplatin with immunotherapy approaches like TIL may offer synergistic benefits. Cisplatin can potentially enhance the efficacy of immunotherapy by increasing tumor antigen presentation and promoting immunogenic cell death, while TIL therapy provides targeted immune response against the tumor.